<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-112822</identifier>
<setSpec>1695-4033</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Role of rituximab in the management of refractory autoimmune cytopenia</dc:title>
<dc:description xml:lang="en">Objectives: This study examined the efficacy of rituximab in children with refractory autoimmune cytopenia. Material and methods: Longitudinal descriptive study comprising a series of clinical cases (n=7) during the period 2003 to 2010. Results: A series 7 patients were included (4 had primary immune thrombocytopenia, 2 autoimmune hemolytic anemia, and 1 autoimmune neutropenia). One patient had received stem cell transplantation. Rituximab was administered intravenously to all patients at a dose of 375mg/mg2 weekly. Four patients received 4 doses. Three patients received 2, 6, and 8 doses, respectively. Overall, 5 patients responded (4 complete responses plus 1 partial response). The median time to achieve complete response was 8.5 weeks (range: 3.5-19.5 weeks). Two patients achieved complete response in the first 3.5 weeks, and the remaining 3 patients between 8.5 and 19.5 weeks. The median time of response was 35.5 weeks (range: 12.5-53.5 weeks). Two patients relapsed. No serious adverse events were recorded. Conclusions: Overall, seventy one percent of patients in this study respond to treatment, 100% of responders decrease their previous treatment. Rituximab was a well tolerated and no related serious side effects were recorded during the study period (AU)</dc:description>
<dc:creator>González Vicent, M</dc:creator>
<dc:creator>Velasco Arribas, M. R</dc:creator>
<dc:creator>Losa Frías, V</dc:creator>
<dc:creator>Sevilla Navarro, J</dc:creator>
<dc:creator>Ortiz Valentín, I</dc:creator>
<dc:creator>García Sánchez, A. M</dc:creator>
<dc:creator>Madero López, L</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo: Evaluar el papel del rituximab en el tratamiento de citopenias autoinmunitarias refractarias a tratamientos convencionales. Material y métodos: Estudio descriptivo longitudinal constituido por una serie de casos clínicos (n = 7) durante el período comprendido entre 2003 y 2010. Resultados: Se recogen 7 pacientes: 4, trombocitopenia inmune primaria; 2, anemia hemolítica autoinmunitaria, y 1, neutropenia autoinmunitaria. Un paciente había recibido trasplante de progenitores hematopoyéticos. La dosis fue de 375mg/m2/semana. Cuatro pacientes recibieron 4 dosis y 3 pacientes recibieron 2, 6 y 8 dosis cada uno. Cinco de los pacientes (71%) cumplieron criterios de respuesta global (completa en 4 pacientes y parcial en 1). A las 8,5 semanas, respondieron la mitad de los pacientes (rango: 3,5-19,5). La mediana de la duración de la respuesta fue de 35,5 semanas (rango: 12,5-53,5). El 100% de los respondedores pudo disminuir su tratamiento previo. Se registraron 2 recaídas. No se registran efectos adversos graves. Conclusiones: El 71% de los pacientes de esta serie responden al tratamiento, disminuyendo el 100% de los respondedores su tratamiento previo. Rituximab es un tratamiento bien tolerado, sin efectos secundarios graves en el período de seguimiento estudiado (AU)</dc:description>
<dc:source>An Pediatr (Barc);78(6): 389-404, jun. 2013. tab</dc:source>
<dc:identifier>ibc-112822</dc:identifier>
<dc:title xml:lang="es">Rituximab en el tratamiento de citopenias autoinmunitarias refractarias a tratamientos convencionales</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d7399</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d2694</dc:subject>
<dc:subject>^d14306^s22057</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d28571</dc:subject>
<dc:subject>^d759^s22057</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d2715</dc:subject>
<dc:subject>^d19563^s22057</dc:subject>
<dc:subject>^d54857^s22083</dc:subject>
<dc:subject>^d920^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201306</dc:date>
</metadata>
</record>
</ibecs-document>
